Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EUDA | Ordinary Shares | Other | +2.78M | 2.78M | Nov 17, 2022 | Direct | F1 | |||
transaction | EUDA | Ordinary Shares | Other | +3K | 3K | Nov 24, 2021 | Direct | F3 | |||
transaction | EUDA | Ordinary Shares | Purchase | +292K | 292K | Nov 24, 2021 | Direct | F4 | |||
holding | EUDA | Ordinary Shares | 2.14M | Nov 17, 2022 | See Footnote | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EUDA | Warrants | Purchase | +292K | 292K | Nov 24, 2021 | Ordinary shares | 146K | $11.50 | Direct | F4, F5, F6 | |||
transaction | EUDA | Rights | Purchase | +292K | 292K | Nov 24, 2021 | Ordinary shares | 29.2K | Direct | F4, F7 |
Id | Content |
---|---|
F1 | The securities reported here were received from Mr. Tan's through his redemption of 8i Capital Limited's and 8i Enterprises Pte Ltd.'s holdings in Watermark Developments Limited at the closing of EUDA Health Holdings Limited's business combination with EUDA Health Limited. The total capital contribution that Mr. Tan invested was $400,000 prior to redemption. |
F2 | The securities reported herein are held by 8i Holdings 2 Pte. Ltd. and may be deemed to be indirectly beneficially owned by Mr. Meng Dong (James) Tan. Mr. Tan disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
F3 | The shares were transferred to Mr. Meng Dong (James) Tan from 8i Holdings 2 Pte. Ltd. |
F4 | The reporting person acquired 292,250 units consisting of ordinary shares, warrants and rights at a purchase price of $10.00 per share. |
F5 | The warrants become exercisable on the later of (i) the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering. |
F6 | The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC. |
F7 | The rights convert automatically into ordinary shares at the completion of the registrant's initial business combination. |